Skip to main content
SpringerLink
Log in

Oral Combination Chemotherapy in the Management of AIDS-Related Lymphoproliferative Malignancies

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

An oral combination chemotherapy regimen initially developed for AIDS-related non-Hodgkin’s lymphoma includes lomustine (CCNU), etoposide, cyclophosphamide, and procarbazine. This regimen takes advantage of oral administration, the in vitro synergy of these drugs and their first-line efficacy in lymphoma, and the ability of lomustine and procarbazine to cross the blood-brain barrier. This regimen was used to treat 38 patients with AIDS-related non-Hodgkin’s lymphoma. The overall objective response rate was 66% (34% complete response rate) with a 5% CNS relapse rate, and a median survival duration of 7.0 months. One-third of the patients survived for 1 year, 11% for 2 years, and half of the patients survived free from progression of their lymphoma. On the basis of these results, this oral regimen was modified and administered to 5 patients with AIDS-related primary CNS lymphoma as part of a sequential combined-modality chemotherapy and radiation regimen. Rapid progression of CNS disease was observed in this group of patients, with a median survival duration of 1.0 month. The identical regimen was administered to 7 patients with AIDS-related Hodgkin’s disease: we observed a 71% partial remission rate and a median survival duration of 7.0 months. Myelosuppression remains the most significant clinical toxicity. Our results with this oral regimen appear comparable to those of standard intravenous combination chemotherapy regimens in patients with AIDS-related non-Hodgkin’s lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greco FA. Introduction to the first comprehensive conference on oral chemotherapy for the treatment of patients with cancer. Drugs 1999; 58 Suppl. 3: 35–41

    Article  PubMed  CAS  Google Scholar 

  2. Freter CD. Acquired immunodeficiency syndrome associated lymphoma. NCI Monogr 1990; 10: 45–54

    Google Scholar 

  3. Remick SC. AIDS-related non-Hodgkin’s lymphoma. Cancer Control 1995; 2: 97–103

    PubMed  Google Scholar 

  4. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336: 1641–8

    Article  PubMed  CAS  Google Scholar 

  5. Ziegler JL, Beckstead JA, Volberding PA, et al. Non-Hodgkin’s lymphoma in 90 homosexual men: relation to generalized lymphadenopathy and acquired immunodeficiency syndrome. N Engl J Med 1984; 311: 565–70

    Article  PubMed  CAS  Google Scholar 

  6. Kaplan LD, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin’s lymphoma in San Francisco. JAMA 1989; 261: 719–24

    Article  PubMed  CAS  Google Scholar 

  7. Gill PS, Levine AM, Krailo M, et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 1987; 5: 1322–8

    PubMed  CAS  Google Scholar 

  8. Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma: results of a randomized trial. J Clin Oncol 1991; 9: 929–40

    PubMed  CAS  Google Scholar 

  9. Levine AM, Wernz JC, Kaplan L, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA 1991; 266: 84–8

    CAS  Google Scholar 

  10. Straus DJ, Huang J, Testa MA, et al. Prognostic factors in the treatment of HIV-associated non-Hodgkin’s lymphoma (HANHL): Analysis of ACTG 142 (low-dose vs standard-dose m-BACOD + GM-CSF). J Acquir Immune Defic Syndr Human Retrovirol 1997; 14: 38A

    Article  Google Scholar 

  11. Sparano JA, Wiernik PH, Strack M, et al. Infusional cyclophosphamide, doxorubicin and etoposide in human immunodeficiency virus and T-cell leukemia virus type 1-related non-Hodgkin’s lymphoma: a highly active regimen. Blood 1993; 81: 2810–5

    PubMed  CAS  Google Scholar 

  12. Sparano JA, Wiernik PH, Strack M, et al. Infusional cyclophos-phamide, doxorubicin and etoposide in HIV-related non-Hodgkin’s lymphoma: a follow up report of a highly active regimen. Leuk Lymphoma 1994; 14: 263–71

    Article  PubMed  CAS  Google Scholar 

  13. Sparano JA, Wiernik PH, Hu X, et al. Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin’s lymphoma. J Clin Oncol 1996; 14: 3026–35

    PubMed  CAS  Google Scholar 

  14. Davis AJ, Goldstein D, Milliken S. Long term follow-up of CEOP in the treatment of HlV-related non-Hodgkin’s lymphoma (NHL). Aust N Z J Med 1998; 28: 28–32

    Article  PubMed  CAS  Google Scholar 

  15. Remick SC, McSharry JJ, Wolf BC, et al. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin’s lymphoma. J Clin Oncol 1993; 11: 1691–702

    PubMed  CAS  Google Scholar 

  16. Carbone P, Spurr C. Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. Cancer Res 1968; 28: 811–22

    PubMed  CAS  Google Scholar 

  17. EORTC, Clinical Screening Group. Epipodophyllotoxin (VP-16-213) in treatment of acute leukaemias, haematosarcomas and solid tumours. BMJ 1973; 3: 199–202

    Article  Google Scholar 

  18. Stolinsky DC, Solomon J, Pugh RP, et al. Clinical experience with procarbazine in Hodgkin’s disease, reticulum cell sarcoma and lymphosarcoma. Cancer 1970; 26: 984–90

    Article  PubMed  CAS  Google Scholar 

  19. Wasserman T, Slavik M, Carter S. Review of CCNU in clinical cancer therapy. Cancer Treat Rev 1974; 1: 131–51

    Article  Google Scholar 

  20. Klimo P. Chemotherapy for aggressive non-Hodgkin’s lymphoma. In: DeVita V, Hellman S, Rosenberg S, editors. Updates: cancer: principles and practice of oncology. Vol. 1. Philadelphia: Lippincott, 1988: 1–12

    Google Scholar 

  21. Lowenbraun S, DeVita V, Serpick A. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine and prednisone in lymphosarcoma and reticulum cell sarcoma. Cancer 1970; 25: 1018–25

    Article  PubMed  CAS  Google Scholar 

  22. Spivack SO. Drugs 5 year later: procarbazine. Ann Intern Med 1974; 81: 795–800

    PubMed  CAS  Google Scholar 

  23. Dombernowsky P, Nissen N. Combination chemotherapy with 4′ demethylepipodophyllotoxin-9-(4,6-0-ethylidine-β-D-glucopyranoside) VP-16-213 (NSC 11141540) in L-1210 leukemia. Eur J Cancer 1976; 12: 181–8

    Article  PubMed  CAS  Google Scholar 

  24. Burchenal J, Lokys L, Turkevich J, et al. Rationale of combination chemotherapy. In: Prestoyko A, Crookes S, Carter S, editors. Cisplatin: Current status and new developments. New York: Academic Press, 1980: 113–23

    Google Scholar 

  25. Garber EK, Fan PT, Bluestone R. Realistic guidelines of corticosteroid therapy in rheumatic disease. Semin Arthritis Rheum 1981; 11: 231–56

    Article  CAS  Google Scholar 

  26. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954–63

    Article  PubMed  CAS  Google Scholar 

  27. Gill PS, Loureiro C, Bernstein-Singer M, et al. Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 110: 937–40

    PubMed  CAS  Google Scholar 

  28. Real FX, Krown SE, Koziner B. Steroid-related development of Kaposi’s sarcoma in a homosexual man with Burkitt’s lymphoma. Am J Med 1986; 80: 119–22

    Article  PubMed  CAS  Google Scholar 

  29. Schulhafer EP, Grossman ME, Fagin G, et al. Steroid-induced Kaposi’s sarcoma in a patient with pre-AIDS. Am J Med 1987; 82: 313–7

    Article  PubMed  CAS  Google Scholar 

  30. Cohen IS, Anderson DW, Virmani R, et al. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med 1986; 315: 628–30

    Article  PubMed  CAS  Google Scholar 

  31. Acierno LJ. Cardiac complications in acquired immunodeficiency syndrome (AIDS): a review. J Am Coll Cardiol 1989; 13: 144–54

    Article  Google Scholar 

  32. Remick SC, Bibighaus MR, Reddy M, et al. Oral combination chemotherapy (CT) in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin’s lymphoma (NHL). J Acquir Immune Defic Syndr Human Retrovirol 1997; 14: 37A

    Article  Google Scholar 

  33. Remick SC, Haase RF, Reddy M, et al. Prospective evaluation of clinical prognostic factors and quality of life (QOL) indices using the Functional Living Index-Cancer (FLIC) and Brief Symptom Inventory (BSL) in patients with AIDS-related neoplasms. J Acquir Immune Defic Syndr Human Retrovirol 1998; 17: 32A

    Article  Google Scholar 

  34. Forsyth PA, Yahalom J, DeAngelis LM. Combined modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 1994; 44: 1473–9

    Article  PubMed  CAS  Google Scholar 

  35. Remick SC, Diamond C, Migliozzi JA, et al. Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome. A retrospective analysis and review of the literature. Medicine (Baltimore) 1990; 69: 345–60

    CAS  Google Scholar 

  36. Baumgartner JE, Rachlin JR, Beckstead JH, et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990; 73: 206–11

    Article  PubMed  CAS  Google Scholar 

  37. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993; 119: 1093–104

    PubMed  CAS  Google Scholar 

  38. Lyter DW, Bryant J, Thackeray R, et al. Incidence of human immunodeficiency virus-related and nonrelated malignancies in a large cohort of homosexual men. J Clin Oncol 1995; 13: 2540–6

    PubMed  CAS  Google Scholar 

  39. Rabkin CS. Epidemiology of malignancies other than Kaposi’s sarcoma and non-Hodgkin’s lymphoma in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 12A

    Article  Google Scholar 

  40. Grulich A, Wan X, Law M, et al. Rates of non-AIDS defining cancers in people with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 13: 18A

    Article  Google Scholar 

  41. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin’s disease and human immunodeficiency virus infection: clinicopathologic and virologie features of 114 patients from the Italian Coop-erative Group on AIDS and Tumors. J Clin Oncol 1995; 13: 1758–67

    PubMed  CAS  Google Scholar 

  42. Levine AM. HIV-associated Hodgkin’s disease. Biologic and clinical aspects. Hematol Oncol Clin North Am 1996; 10: 1135–48

    Article  PubMed  CAS  Google Scholar 

  43. Remick SC, Doshi S, Bibighaus M, et al. Oral combination chemotherapy (CT) in the treatment of AIDS-associated Hodgkin’s disease (HD). Proc Am Soc Clin Oncol 1996; 15: 307A

    Google Scholar 

  44. Gershwin MF, Goetzl EJ, Steinberg AD. Cyclophosphamide: use in practice. Ann Intern Med 1974; 80: 531–40

    PubMed  CAS  Google Scholar 

  45. Issell BF, Crooke ST. Etoposide (VP-16-213). Cancer Treat Rev 1979; 6: 107–24

    Article  PubMed  CAS  Google Scholar 

  46. O’Dwyer PJ, Leyland-Jones B, Alonso MT, et al. Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med 1985; 312: 692–700

    Article  PubMed  Google Scholar 

  47. Wiernik PH. Chemotherapy of Hodgkin’s disease. In: De Vita Jr VT, Hellman S, Rosenberg SA, editors. Updates: Cancer. Principles and practice of oncology. Vol. 2. Philadelphia: Lippincott, 1988: 1–12

    Google Scholar 

  48. DeVita Jr VT, Serpick A, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 1970; 73: 881–95

    PubMed  Google Scholar 

  49. DeVita Jr VT, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587–95

    Google Scholar 

  50. Bakemeier RF, Anderson JR, Costello W, et al. BCVPP chemo therapy for advanced Hodgkin’s disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Ann Intern Med 1984; 101: 447–56

    CAS  Google Scholar 

  51. Buzaid AC, Lippman SM, Miller TP. Salvage therapy of advanced Hodgkin’s disease. Critical appraisal of curative potential. Am J Med 1987; 83: 523–32

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Case Western Reserve University, and the Ireland Cancer Center at University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, Ohio, 44106, USA

    Scot C. Remick, Mark Craffey & Afshin Dowlati

  2. Department of Statistics, Case Western Reserve University, Cleveland, Ohio, USA

    Nell Sedransk & Neepa Subramanian

  3. Department of Psychology, State University of New York at Albany, Albany, New York, USA

    Richard Haase

  4. Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA

    Tipu Nazeer

  5. Division of HIV Medicine, Albany Medical College, Albany, New York, USA

    Carm Ramnes

  6. Division of Hematology and Medical Oncology, Albany Medical College, Albany, New York, USA

    Christina Blanchard & David Mastrianni

  7. H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA

    Lodovicco Balducci, John Horton & John C. Ruckdeschel

Authors
  1. Scot C. Remick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nell Sedransk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Haase
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark Craffey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Neepa Subramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Afshin Dowlati
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tipu Nazeer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carm Ramnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Christina Blanchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. David Mastrianni
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lodovicco Balducci
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. John Horton
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. John C. Ruckdeschel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scot C. Remick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Remick, S.C., Sedransk, N., Haase, R. et al. Oral Combination Chemotherapy in the Management of AIDS-Related Lymphoproliferative Malignancies. Drugs 58 (Suppl 3), 99–107 (1999). https://doi.org/10.2165/00003495-199958003-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958003-00014

Keywords

Search

Navigation